Donor-derived solid malignancies after hematopoietic stem cell transplantation.
Allogeneic hematopoietic stem cell transplantation is considered to be a potentially therapeutic strategy for various hematopoietic benign diseases and malignancies. The growing number of reports on long-term survivors after hematopoietic stem cell transplantation reveals the major merits of this strategy. However, such cohorts remain at high risk of potential late complications, including the development of secondary solid malignancies. An increasing number of cases of secondary malignancies originated from recipients, donors, or unknown sources has been reported. In this review, we focus on latest clinical evidence of donor-derived solid malignancies after allogeneic hematopoietic stem cell transplantation, postulate related potential mechanisms, and further address novel indications as well as feasible therapeutic and preventive perspectives.
Hu
Yong-xian
YX
Center of Hematology and Bone Marrow Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, 310003 Hangzhou, Zhejiang, China.
Cui
Qu
Q
Liang
Bin
B
Huang
He
H
D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D019520:Living Donors; D009369:Neoplasms / Q000209:etiology* / Q000517:prevention & control*